A cytotoxic peptide-drug conjugate for tumor-specific delivery of co-injected molecules

Area of Science:

• Oncology
• Biomedical Engineering
• Drug Delivery

Background:

• Ideal cancer therapies require enhanced anti-tumor efficacy and minimized side effects.
• Integrin-binding peptide (iRGD) facilitates tumor-specific drug penetration and acts as a delivery scaffold.
• Monomethyl auristatin F (MMAF) is a potent antimitotic agent used in cancer therapy.

Purpose of the Study:

• To synthesize and characterize an iRGD-MMAF conjugate for dual function in cancer therapy.
• To evaluate the conjugate's tumor-specific cytotoxicity and drug delivery capabilities.
• To assess the iRGD component's ability to enhance co-injected agent delivery.

Main Methods:

• Synthesis of an iRGD-MMAF conjugate.
• In vitro studies using cultured tumor cells to assess internalization and cytotoxicity.
• In vivo studies in mice to evaluate systemic administration, tumor homing, and tissue penetration.
• Assessment of the conjugate's efficacy as a scaffold for co-injected molecules.

Main Results:

• The iRGD-MMAF conjugate demonstrated αv integrin-dependent internalization and killing of tumor cells.
• Systemic injection resulted in selective tumor homing and extensive extravascular spread within tumors.
• The conjugate significantly enhanced tumor-specific entry of a co-injected molecule.
• The modified iRGD peptide retained its drug delivery scaffold function.

Conclusions:

• Chemically modified iRGD peptides can retain their drug delivery capabilities while incorporating therapeutic benefits.
• The iRGD-MMAF conjugate shows promise as a dual-function agent for targeted cancer therapy.
• This approach offers a strategy for improving the efficacy of cancer treatments through enhanced drug delivery.